Big Pharma


Also found in: Dictionary, Wikipedia.

Big Pharma

(fär′mə)
n. Informal
The pharmaceutical industry.
A term that encompasses the largest players in the pharmaceutical, including AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Maxim, Merck, Monsanto, Pfizer, Roche, Tanabe, Wyeth
Mentioned in ?
References in periodicals archive ?
Comment: The current business friendly stance at the FDA is unlikely to change next year, while M and A could see an uptick, driven by big pharma and big biotech's need to re-stock pipelines and US tax reforms, according to EP Vantage
Instead of going it alone, Big Pharma now turns to small biotechs--a big change over the past two decades.
After Indias decision to award compulsory licensing (CL) to Natco for Nexavar, which was patented by Bayer Healthcare, big pharma companies are raising concerns surrounding the possible adverse impacts of this decision on innovator drug companies.
This is the reason I psychologically squirrel into the world of low-beta defensive investing, the world of megacap Big Pharma.
Top 50 Big Pharma Partnering and M&A Deal Trends provides the user with the following key benefits:
Big pharma does not have the facilities and staff they used to rely on.
The transformation of Big Pharma has been driven as much by new technologies that have enabled development of new products that improve disease outcomes and command high prices as by the expiring patents on many top-selling small molecule drugs, according to Tufts CSDD director Kenneth Kaitin.
The business intelligence outfit's latest study states that with squeezed Research and Development (R and D) budgets, Big Pharma is finding greater value in employing Contract Research Organizations (CROs) in emerging nations for the management of clinical trials.
MUMBAI -- Faced with losses once its blockbusters start losing patents, Big Pharma is now devising strategies to counter the impact.
4, page 10) that bears repeating because Big Pharma is coming through with threats--actually validating the studies
The choice of outsourcing operating model(s) and the executive governance to implement the model(s) of choice are critical decisions for R&D leadership teams in Big Pharma.
Last week, after being reported in the Los Angeles Times, the White House confirmed it has prom ised Big Pharma that any healthcare legislation will bar the government from using its huge purchasing power to negotiate lower drug prices.